SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
|---|
| Accounting Policies [Abstract] |
|
| SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES |
The
following potentially dilutive securities have been excluded from the computations of weighted average shares of Common Stock outstanding
as of December 31, 2025 and 2024, as they would be anti-dilutive:
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES
| |
|
|
|
|
|
|
| |
|
As of December 31, |
|
| |
|
2025 |
|
|
2024 |
|
| Shares underlying options outstanding |
|
|
9,055 |
|
|
|
9,649 |
|
| Shares underlying convertible preferred stock |
|
|
101,448 |
|
|
|
— |
|
| Shares underlying warrants outstanding |
|
|
1,348,494 |
|
|
|
409,847 |
|
| Shares underlying unvested restricted stock |
|
|
4,371 |
|
|
|
11,638 |
|
| Anti-dilutive securities |
|
|
1,463,368 |
|
|
|
431,134 |
|
|
| SCHEDULE OF REVENUE RECOGNITION |
SCHEDULE OF REVENUE RECOGNITION
| |
|
|
|
|
|
|
| |
|
Year Ended December 31,
|
|
| |
|
2025 |
|
|
2024 |
|
| Patient
service fees1 |
|
$ |
4,971,342 |
|
|
$ |
8,175,670 |
|
| Histology service fees |
|
|
1,116,912 |
|
|
|
1,103,751 |
|
| Medical director fees |
|
|
68,268 |
|
|
|
66,576 |
|
| Department of Defense observational studies |
|
|
577 |
|
|
|
8,654 |
|
| Other revenues |
|
|
4,860 |
|
|
|
7,371 |
|
| Total net revenue |
|
$ |
6,161,959 |
|
|
$ |
9,362,022 |
|
| 1 |
Patient
services fees include direct billing for CyPath® Lung diagnostic test of approximately $963,000 and $516,000 for the years ended
December 31, 2025 and 2024. |
|
| SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE |
Property
and equipment are carried at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the
estimated useful life of the asset. Amortization of leasehold improvements is computed using the shorter of the lease term or estimated
useful life of the asset. Additions and improvements are capitalized, while repairs and maintenance are expensed as incurred. Useful
lives of each asset class are as follows:
SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE
| Asset
Category |
|
Useful
Life |
| Computer
equipment |
|
3-5
years |
| Computer
software |
|
3
years |
| Equipment |
|
3-5
years |
| Furniture
and fixtures |
|
5-7
years |
| Vehicles |
|
5
years |
| Leasehold
improvements |
|
Lesser
of lease term or useful life |
|
| SCHEDULE OF INTANGIBLE ASSETS |
SCHEDULE OF INTANGIBLE ASSETS
| |
|
|
|
|
- |
|
| |
|
December 31, |
|
| |
|
2025 |
|
|
2024 |
|
| Cost |
|
|
|
|
|
|
|
|
| Goodwill |
|
$ |
1,404,486 |
|
|
$ |
1,404,486 |
|
| Trade names and trademarks |
|
|
150,000 |
|
|
|
150,000 |
|
| Customer relationships |
|
|
700,000 |
|
|
|
700,000 |
|
| Cost |
|
|
2,254,486 |
|
|
|
2,254,486 |
|
| Accumulated amortization |
|
|
|
|
|
|
|
|
| Trade names and trademarks |
|
|
(19,028 |
) |
|
|
(10,694 |
) |
| Customer relationships |
|
|
(114,166 |
) |
|
|
(64,167 |
) |
| Accumulated amortization |
|
|
(133,194 |
) |
|
|
(74,861 |
) |
| Intangible assets, net |
|
$ |
2,121,292 |
|
|
$ |
2,179,625 |
|
|
| SCHEDULE OF ESTIMATED AMORTIZATION OF INTANGIBLE ASSETS |
The
estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as
of December 31, 2025 is as follows:
SCHEDULE OF ESTIMATED AMORTIZATION
OF INTANGIBLE ASSETS
| Year Ending December 31, |
|
|
|
| 2026 |
|
$ |
58,333 |
|
| 2027 |
|
|
58,333 |
|
| 2028 |
|
|
58,333 |
|
| 2029 |
|
|
58,333 |
|
| 2030 |
|
|
58,333 |
|
| Thereafter |
|
|
425,141 |
|
| Total |
|
$ |
716,806 |
|
|
| SCHEDULE OF SEGMENT INFORMATION |
SCHEDULE
OF SEGMENT INFORMATION
| |
|
|
|
|
|
|
| |
|
As of December 31, |
|
| |
|
2025 |
|
|
2024 |
|
| Net revenues: |
|
|
|
|
|
|
|
|
| Diagnostic R&D |
|
$ |
577 |
|
|
$ |
8,654 |
|
| Laboratory services |
|
|
6,161,382 |
|
|
|
9,353,368 |
|
| Total net revenues |
|
|
6,161,959 |
|
|
|
9,362,022 |
|
| |
|
|
|
|
|
|
|
|
| Operating expenses: |
|
|
|
|
|
|
|
|
| Diagnostic R&D |
|
|
(2,089,103 |
) |
|
|
(1,782,882 |
) |
| Laboratory services |
|
|
(6,952,050 |
) |
|
|
(9,946,452 |
) |
| General corporate activities |
|
|
(7,693,314 |
) |
|
|
(6,586,133 |
) |
| Total operating loss |
|
|
(10,572,508 |
) |
|
|
(8,953,445 |
) |
| |
|
|
|
|
|
|
|
|
| Non-operating expense, net |
|
|
(4,293,204 |
) |
|
|
(74,736 |
) |
| Income tax expense |
|
|
(44,042 |
) |
|
|
(11,650 |
) |
| Net loss |
|
$ |
(14,909,754 |
) |
|
$ |
(9,039,831 |
) |
|